The identification of protective factors for Diabetic Retinopathy (DR) and Diabetic Nephropathy (DN) could provide important biomarkers and therapeutic agents to prevent and halt these two toxic complications from significantly diminishing quality of life. Using a unique population of type 1 diabetic (T1DM) patients with more than 50 years of disease (Medalists), we have begun to identify potential protective factors for DR and DN through pre and post mortem studies. We have extensively characterized over 600 Medalists through clinical examination, mixed meal tolerance test, extensive ophthalmic examination, and medical history questionnaires. Surprisingly, 35% have no or only mild DR (ETDRS <53), and less than 14% have DN (ACR <70 mcg/mg). Post-mortem histologic examinations confirm these findings. Thus far, post-mortem specimens from over 16 Medalist Study participants have been donated. Proteomic mapping of the specimens from the retina, vitreous, and renal glomeruli have identified a first set of potential protective factors for DR and DN. This was done by comparing protein expression between affected and unaffected tissues. According to pathway mapping and literature review, the fourteen candidate proteins identified in the glomerular analysis are all involved in fuel metabolism. The 10 factors identified in the retina analysis are involved in membrane recycling, transport, recovery of phototransduction, and retinal function. Bioinformatic pathway analyses demonstrate that the candidates identified for DR do not overlap with those for DN;however, both sets of protective factors suggest that more vibrant and metabolically active tissues exist in Medalists without DR or DN compared to those with the respective conditions. This study proposes to measure all of the identified and validated candidates in the plasma and circulating cells in the Medalists and in another unusual group of diabetic patients with ultra-fast progression. Additionally, the ability to protect against hyperglycemic exposure will be studied in cultured retinal vascular and renal glomerular and tubular cell models of DR and DN. We will also be able to determine the biological actions of these potential protective factors both in cell culture models and in vivo animal models of diabetes. From these translational studies, we will be able to identify and confirm potential protective factors associated with DR and DN.

Public Health Relevance

Clinically, studies in diabetic patients who have survived greater than 50 years of disease duration clearly have demonstrated that endogenous protective factors can prevent and delay for extreme periods of time the onset of diabetic microvascular complications. Thus, therapeutic approach in the future for diabetic vascular complications needs to decrease the toxic effects of hyperglycemia as well as increase the actions of protective/survival factors in order to be effective.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Type 1 Diabetes Targeted Research Award (DP3)
Project #
1DP3DK094333-01
Application #
8241364
Study Section
Special Emphasis Panel (ZDK1-GRB-J (O1))
Program Officer
Jones, Teresa L Z
Project Start
2011-09-30
Project End
2016-06-30
Budget Start
2011-09-30
Budget End
2016-06-30
Support Year
1
Fiscal Year
2011
Total Cost
$3,963,638
Indirect Cost
Name
Joslin Diabetes Center
Department
Type
DUNS #
071723084
City
Boston
State
MA
Country
United States
Zip Code
02215
Musen, Gail; Tinsley, Liane J; Marcinkowski, Katrina A et al. (2018) Cognitive Function Deficits Associated With Long-Duration Type 1 Diabetes and Vascular Complications. Diabetes Care 41:1749-1756
Gordin, Daniel; Harjutsalo, Valma; Tinsley, Liane et al. (2018) Differential Association of Microvascular Attributions With Cardiovascular Disease in Patients With Long Duration of Type 1 Diabetes. Diabetes Care 41:815-822
Maddaloni, Ernesto; D'Eon, Stephanie; Hastings, Stephanie et al. (2017) Bone health in subjects with type 1 diabetes for more than 50 years. Acta Diabetol 54:479-488
Maddaloni, Ernesto; Xia, Yu; Park, Kyoungmin et al. (2017) High density lipoprotein modulates osteocalcin expression in circulating monocytes: a potential protective mechanism for cardiovascular disease in type 1 diabetes. Cardiovasc Diabetol 16:116
Qi, Weier; Keenan, Hillary A; Li, Qian et al. (2017) Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat Med 23:753-762
Tinsley, Liane J; Kupelian, Varant; D'Eon, Stephanie A et al. (2017) Association of Glycemic Control With Reduced Risk for Large-Vessel Disease After More Than 50 Years of Type 1 Diabetes. J Clin Endocrinol Metab 102:3704-3711
Khamaisi, Mogher; Katagiri, Sayaka; Keenan, Hillary et al. (2016) PKC? inhibition normalizes the wound-healing capacity of diabetic human fibroblasts. J Clin Invest 126:837-53
King, George L; Park, Kyoungmin; Li, Qian (2016) Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture. Diabetes 65:1462-71
He, Zhiheng H; D'Eon, Stephanie A; Tinsley, Liane J et al. (2015) Cardiovascular disease protection in long-duration type 1 diabetes and sex differences. Diabetes Care 38:e73-4
Bhatt, Shweta; Gupta, Manoj K; Khamaisi, Mogher et al. (2015) Preserved DNA Damage Checkpoint Pathway Protects against Complications in Long-Standing Type 1 Diabetes. Cell Metab 22:239-52

Showing the most recent 10 out of 12 publications